Heart Valves in Europe: The Mix Will Change
This article was originally published in Start Up
Executive Summary
According to "European Markets for Heart Valve Repair and Replacement Products," Medtech Insight's recent report, in the coming years growth in the heart valve industry will be somewhat flat in Europe-with a compound annual growth rate in the overall number of procedures of 1.6% between now and 2013. However, that number reflects a drop in the number of mechanical valves used, and a rise in tissue valves, which are enjoying increased uptake with each generation of technological improvements.
You may also be interested in...
Biologic Valves Are As Good As Mechanical Valves In Younger Patients, Study Shows
Bioprosthetic replacement heart valves may be a reasonable alternative to mechanical valves in patients aged 50 to 69 years, according to a retrospective cohort analysis of 4,253 patients.
Abbott Moves into Heart Valves with Evalve Deal
The hottest major interventional cardiology company, Abbott, moves into the hottest interventional clinical space, catheter-based heart valve therapy, with the acquisition of Evalve, providing Abbott with a platform to build a structural heart disease device business.
Evalve, Mitralign Deals: Heart Valves Draw New Device Investors
Over the last few years, interventional heart valve technologies have been among the most popular segments of the cardiovascular device market with venture investors. This popularity has resulted in some VCs concluding that the space has become saturated. While the market may be getting tougher to enter for newcomers, the successful financing rounds recently closed by Evalve and Mitralign show that investors--including new device investors--remain bullish on companies that can demonstrate an effective percutaneous alternative to existing surgical procedures.